Metraipolis › archive › dc_160ddc44d7bf
Development and validation of the NEOS2 score for prediction of long-term outcomes and improvement after first-line immunotherapy in patients with anti-NMDAR… — Europe PMC PMID:41488792
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41488792
- DOI
- 10.1016/j.lanepe.2025.101562
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T17:31:41.579Z
- SHA-256 of the archived text
e15972979e2dc3a58c82fe86b93ce66f34fec26b90031f83f50f6931454eb189- Stable URL of this page
https://metraipolis.com/documento/dc_160ddc44d7bf
How to cite
Development and validation of the NEOS2 score for prediction of long-term outcomes and improvement after first-line immunotherapy in patients with anti-NMDAR… — Europe PMC PMID:41488792 — Europe PMC (en), https://europepmc.org/article/MED/41488792 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_160ddc44d7bf (Metraipolis archive dc_160ddc44d7bf, sha256 e15972979e2dc3a58c82fe86b93ce66f34fec26b90031f83f50f6931454eb189)
BibTeX
@misc{dc160ddc44d7bf,
title = {Development and validation of the NEOS2 score for prediction of long-term outcomes and improvement after first-line immunotherapy in patients with anti-NMDAR… — Europe PMC PMID:41488792},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41488792},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_160ddc44d7bf; sha256 e15972979e2dc3a58c82fe86b93ce66f34fec26b90031f83f50f6931454eb189},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41488792. Agents can read the archived copy with the MCP tool read_document.